Polycyclo Ring System Having The Oxazine Ring As One Of The Cyclos Patents (Class 544/99)
  • Patent number: 10263193
    Abstract: Disclosed are a heterocyclic compound represented by the following Chemical Formula having proper energy level, and excellent electrochemical stability and thermal stability, and an organic light emitting device using the same:
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: April 16, 2019
    Assignee: LG CHEM, LTD.
    Inventors: Minyoung Kang, Dong Hoon Lee, Boonjae Jang, Jungi Jang, Seong So Kim
  • Patent number: 9096531
    Abstract: Provided is a novel compound which shows an antagonistic effect against T-type calcium channels, and is useful as a pharmaceutical product. A compound represented by general formula (I), and a pharmaceutical agent containing the same, are disclosed: wherein n represents the number of nitrogen atoms contained in the 6-membered fused aromatic ring, and is 0, 1 or 2; p represents the number of nitrogen atoms contained in the 6-membered aromatic ring, and is 0 or 1; X represents an oxygen atom, —SO2— or —N(R9)—; and R1 to R5 each represents a hydrogen atom or other substituents.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 4, 2015
    Assignee: TOA EIYO LTD.
    Inventors: Hidekazu Masaki, Hiroshi Takasugi, Tomoyuki Nagayama, Ryutaro Shimono, Yujiro Uchino, Koichi Takayanagi
  • Publication number: 20150139915
    Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Stefan Worgall, Tilla S. Worgall
  • Patent number: 9035042
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: May 19, 2015
    Assignee: ATTO-TEC GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Patent number: 9028728
    Abstract: The present invention relates to photochromic materials that include one or more indeno-fused naphthopyrans that have particular groups at the 7, 11, and 13 positions thereof, and at the position alpha to the oxygen of the pyran ring thereof. With some embodiments, hydrogen or an alkoxy group is bonded to the 7 position, an optionally substituted phenyl is bonded to the 11 position, two alkyl groups are bonded to the 13 position, and two optionally substituted phenyl groups are bonded to the position alpha to the oxygen of the pyran ring of the indeno-fused naphthopyran compound. The 13 position of the indeno-fused naphthopyrans is free of ether groups in which an ether oxygen is bonded to the 13 position, and hydroxyl. The present invention also relates to photochromic articles and compositions that include such indeno-fused naphthopyrans.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: May 12, 2015
    Assignee: Transitions Optical, Inc.
    Inventors: Kevin E. Bancroft, Anu Chopra, Xiao-Man Dai, Beon-Kyu Kim, David B. Knowles, Jason R. Lewis, Victor A. Montes, Stephen D. Straight, Massimiliano Tomasulo, Barry Van Gemert, Robert W. Walters, Wenjing Xiao, Huayun Yu, Elizabeth A. Zezinka
  • Publication number: 20150080366
    Abstract: Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Application
    Filed: April 3, 2013
    Publication date: March 19, 2015
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Lee Fader, Pierre Louis Beaulieu, Murray Bailey, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Oliver Hucke, Marc-André Joly, Mélissa Leblanc, Olivier Lepage, Benoit Moreau, Julie Naud, Martin Poirier, Elisia Villemure
  • Publication number: 20150057270
    Abstract: The invention provides prodrugs of DNA-reactive analogs of duocarmycin and CC-1065 anticancer agents, wherein a cyclic prodrug form, such as carbamate, thionocarbamate, or carbamimidate, can be hydrolyzed by the patient in vivo to yield a respective bioactive agent comprising a DNA-alkylating moiety and a binding/targeting moiety. The DNA-reactive moiety is a ?-spiro-cyclohexenone fused to a heterocyclyl group which can be produced by endogenous hydrolysis of a cyclic carbamate prodrug of the invention. The cyclic carbamate prodrug produces no residual byproduct during activation in vivo. Methods of synthesis and biological methods and data are also provided.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 26, 2015
    Inventor: Dale L. Boger
  • Publication number: 20140364412
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • Publication number: 20140303144
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 9, 2014
    Applicant: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty
  • Publication number: 20140275526
    Abstract: This disclosure relates to compounds containing a fluorophore covalently bonded to at least one protected sulfonate group of formula (I): in which X and R2-R5 are defined in the specification. This disclosure also relates to use of these compounds as dyes in an imaging methods, as well as intermediates that can be used to prepare these compounds.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicant: University of Massachusetts
    Inventors: Stephen C. Miller, Steven M. Pauff, Adam Choi
  • Publication number: 20140256717
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 11, 2014
    Applicant: Centro Nacional de Investigaciones Oncológicas (CNIO)
    Inventors: Joaquín Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martin Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
  • Publication number: 20140228353
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 14, 2014
    Applicant: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvvajit Chakravarty
  • Publication number: 20140206663
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Inventors: Jianfei Wang, Eric C. Breinlinger, Martine Barth, Michael M. Friedman, Fabrice Guillier, Maria A. Argiriadi, Jeremy Edmunds, Dominique Potin, Adrian D. Hobson, Wentao Wu, Dominique Bonafoux, Didier Thomas, Dawn M. George, Linlin Dai, Yang Zhang
  • Publication number: 20140199264
    Abstract: The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: March 16, 2012
    Publication date: July 17, 2014
    Inventors: Craig A. Coburn, Stuart B. Rosenblum, Joseph A. Kozlowski, Richard Soll, Hao Wu, Bin Hu, Bin Zhong, Dahai Wang, Changmao Shen, Fei Sun
  • Patent number: 8679776
    Abstract: Novel, activatable dyes, such as photoactivatable dyes, e.g., oxazine dyes, are described. Some of the dyes are targeting dyes that can, e.g., target biomolecules, such as polypeptides, proteins, or nucleic acids. Upon activation, such as by irradiation, the novel dyes rapidly turn on their fluorescence and emit light, such as near-IR light with spatial and temporal precision.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: March 25, 2014
    Assignee: University of Massachusetts
    Inventor: Stephen C. Miller
  • Publication number: 20140080821
    Abstract: Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 20, 2014
    Applicant: The Regents of the University of California
    Inventors: Alan S. Verkman, David S. Snyder
  • Publication number: 20140042370
    Abstract: The present invention relates to compounds of the formula (1) and formula (2), which are suitable for use in electronic devices, in particular in organic electroluminescent devices.
    Type: Application
    Filed: March 26, 2012
    Publication date: February 13, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Irina Martynova, Christof Pflumm, Amir Hossain Parham, Christof Pflumm, Rémi Manouk Anémian, Teresa Mujica-Fernaud, Claire De Nonancourt
  • Patent number: 8614317
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: December 24, 2013
    Assignee: Atto-Tec GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Publication number: 20130334461
    Abstract: Provided are a polymerizable liquid crystal composition, a coating material, a medium, and a polarizing device each produced using a polymerizable liquid crystal compound and a colorant and each capable of producing polarized light suitable for polarizing devices, and also a novel naphtholactam derivative, a novel coumarin derivative, a novel Nile Red derivative, and a novel anthracene derivative each suitable for use as the colorant. Specifically provided are a polymerizable liquid crystal composition containing (A) at least one liquid crystal compound having a polymerizable functional group, (B) at least one colorant, and (C) a polymerization initiator, and a novel naphtholactam derivative of formula (IV?), a novel coumarin derivative of formula (VI?), a novel Nile Red derivative of formula (VII?), and a novel anthracene derivative of formula (VIII?) each suitable for use as the colorant (B).
    Type: Application
    Filed: March 15, 2012
    Publication date: December 19, 2013
    Applicant: ADEKA CORPORATION
    Inventors: Yusuke Kubota, Masatomi Irisawa, Toru Yano, Ken Matsumoto
  • Patent number: 8608988
    Abstract: The present invention provides a curable, organic polymeric photochromic composition comprising: a photochromic amount of at least one photochromic material; a polymeric polyol having carbonate groups along its backbone and having a number average molecular weight greater than 5000 g/mole; and a curing agent having reactive functional groups capable of reacting with hydroxyl groups on the polymeric polyol. After curing and after the Photochromic Performance Test the composition demonstrates a T1/2 fade rate of less than 200 seconds. Also provided is a photochromic article comprising a rigid substrate and a photochromic organic polymeric coating applied to a surface of the substrate. The photochromic organic polymeric coating comprises the composition described above.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 17, 2013
    Assignee: Transitions Optical, Inc.
    Inventors: Steven E. Bowles, Cynthia Kutchko, Paul H. Lamers, Jason R. Lewis, David E. Sartori, Robert W. Walters, Feng Wang
  • Publication number: 20130313532
    Abstract: [Problem] To provide a charge transporting material which allows for a low driving voltage and is superior in luminous efficiency and durability. [Means for resolution] A charge transporting material comprising a compound represented by any one of the following general formula (1-1) to general formula (1-3): wherein R111 to R114, R121 to R125 and R131 to R135 each independently represent a hydrogen atom or a substituent, and may be bound together to form a ring; L111 to L113 each independently represent O or S; L121 to L123 each independently represent a single bond or a divalent linking group; and Ar111 to Ar113 each independently represent an aryl group or a heteroaryl group.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 28, 2013
    Applicant: UDC IRELAND LIMITED
    Inventors: Kousuke WATANABE, Yosuke YAMAMOTO, Wataru SOTOYAMA
  • Publication number: 20130302416
    Abstract: New substituted tricyclic compounds of formula (I) are described, wherein R1, R2, X, Y, Z are herein defined, having protein kinase inhibiting activity. The invention includes methods to prepare the compounds of formula (I), pharmaceutical compositions containing them, and their use in therapy, in particular for the treatment of diseases caused by and/or associated with dysregulated activity of protein kinase.
    Type: Application
    Filed: January 19, 2012
    Publication date: November 14, 2013
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Marina Caldarelli, Francesco Casuscelli, Daniele Donati, Danilo Mirizzi, Francesca Quartieri, Marco Silvagni
  • Publication number: 20130274470
    Abstract: Provided herein are triazolium carbine catalysts useful for asymmetric hydration, fluorination, and deuteration, and processes for their preparation. Also provided are synthetic reactions in which these catalysts are used, in particular, in stereoselective formation of carbon-chlorine, carbon-hydrogen, carbon-fluorine, and carbon-deuterium bonds.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 17, 2013
    Inventors: Tomislav Rovis, Harit U. Vora
  • Patent number: 8546383
    Abstract: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: October 1, 2013
    Assignee: 3M Innovative Properties Company
    Inventors: George W. Griesgraber, Tushar A. Kshirsagar, Azim A. Celebi, Sarah J. Slania, Michael E. Danielson, Michael J. Rice, Joshua R. Wurst
  • Publication number: 20130225558
    Abstract: This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: February 18, 2011
    Publication date: August 29, 2013
    Inventors: Sarvajit Chakravarty, Barry Patrick Hart, Rajendra Parasmal Jain
  • Publication number: 20130217672
    Abstract: A (+)-3-hydroxymorphinan-based polycycle derivative of formula (I) is effective as a neuroprotective agent for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and ischemic stroke.
    Type: Application
    Filed: May 13, 2011
    Publication date: August 22, 2013
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jong Yup Kim, Jeongmin Kim, Kwang Woo Ahn
  • Publication number: 20130210803
    Abstract: This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: February 18, 2011
    Publication date: August 15, 2013
    Inventors: Sarvajit Chakravarty, Barry Patrick Hart, Rajendra Parasmal Jain
  • Patent number: 8501658
    Abstract: This invention provides a convenient method for converting imines and other electrophiles into heterocyclic ring systems. The process does not require the use of metallic reagents, and is catalyzed by an organic heterocyclic carbene catalyst. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. Chiral heterocyclic carbene catalysts of the invention and methods of using these catalysts produce chiral heterocycles in high enantiomeric and diastereomeric excess.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: August 6, 2013
    Assignee: The Regents of the University of California
    Inventors: Jeffrey Bode, Ming He, Justin Struble
  • Publication number: 20130149251
    Abstract: The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 13, 2013
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Scott A. Hilderbrand, Ralph Weissleder, Peter Panizzi, Jason R. McCarthy
  • Publication number: 20130123217
    Abstract: The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10.
    Type: Application
    Filed: December 13, 2012
    Publication date: May 16, 2013
    Applicant: NEUMEDICS
    Inventor: Neumedics
  • Patent number: 8388872
    Abstract: The present invention provides a photochromic material which is an indeno-fused naphthopyran of structural formulas I or II, having a pi-conjugation extending group bonded to the 11-position of the indeno-fused naphthopyran, the pi-conjugation extending group having at least one pendent halo-substituted group bonded thereto. The pi-conjugation extending group extends the pi-conjugation system of said indeno-fused naphthopyran. The 13-position of the indeno-fused naphthopyran is substantially free of spiro-substituents. The invention further provides photochromic materials of specified structure, photochromic compositions, photochromic articles and optical elements that include the photochromic material.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: March 5, 2013
    Assignee: Transitions Optical, Inc.
    Inventors: Anu Chopra, Jun Deng, Beon-Kyu Kim, David B. Knowles, Frank F. Molock, Jr., Victor A. Montes, Stephen D. Straight, Wenjing Xiao, Huayun Yu
  • Publication number: 20120328530
    Abstract: A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R2, R3 and R4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R1 is not methyl or hydrogen when each of R3 and R4 is methyl or hydrogen.
    Type: Application
    Filed: March 11, 2011
    Publication date: December 27, 2012
    Applicant: PHARMALUCIA LIMITED
    Inventor: Mark Wainwright
  • Publication number: 20120315661
    Abstract: The present invention describes novel dyes, including coumarins, rhodamines, and rhodols that incorporate additional fused aromatic rings. The dyes of the invention absorb at a longer wavelength than structurally similar dyes that do not possess the fused aromatic rings. Many of the dyes of the invention are useful fluorescent dyes. The invention includes chemically reactive dyes, dye-conjugates, and the use of such dyes in staining samples and detecting ligands or other analytes.
    Type: Application
    Filed: May 14, 2012
    Publication date: December 13, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Zhenjun DIWU, Jixiang LIU, Kyle GEE
  • Publication number: 20120283220
    Abstract: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.
    Type: Application
    Filed: September 22, 2010
    Publication date: November 8, 2012
    Inventors: Kuo-Hsiung Lee, Xiaoming Yang, Qian Shi, Kenneth F. Bastow, Che-Ming Teng, Tse-Ming Hong, Pan-Chyr Yang, Shuenn-Chen Yang
  • Patent number: 8288374
    Abstract: Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine compound represented by General formula (1) or a salt compound of the same, in particular, an agent for treating and/or preventing infection with a protozoa such as malaria, leishmaniasis, African trypanosomiasis, Chagas disease, toxoplasmosis, lymphatic filariasis, babesiosis or coccidium disease; and a novel compound which is contained therein as the active ingredient.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: October 16, 2012
    Assignees: Hoshi University, Synstar Japan Co., Ltd., Swiss Tropical and Public Health Institute, FUJIFILM Corporation
    Inventors: Masataka Ihara, Jian-Feng Ge, Chika Arai, Nasser Saad Mohamed Ismail, Mei Yang, Isamu Itoh, Reto Brun
  • Publication number: 20120227802
    Abstract: The present invention provides a organic compound of the general structural formula 1 and photovoltaic device and photovoltaic layer comprising thereof Said organic compound forms rod-like supramolecules and absorbs electromagnetic radiation in at least one predetermined spectral subrange within a wavelength range from 400 to 3000 nm with excitation of electron-hole pairs. The polycyclic core Cor1, the bridging group B, and the polycyclic core Cor2 form a molecular system selected from the list comprising donor-bridge-acceptor-bridge-donor and acceptor-bridge-donor-bridge-acceptor in which a dissociation of excited electron-hole pairs is carried out. A solution of the organic compound or its salt forms a solid photovoltaic layer on a substrate.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicant: Cryscade Solar Limited
    Inventors: Pavel KHOKHLOV, Pavel Ivan Lazarev, Alexey Nokel
  • Publication number: 20120232057
    Abstract: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    Type: Application
    Filed: May 25, 2012
    Publication date: September 13, 2012
    Inventors: George W. GRIESGRABER, Tushar A. KSHIRSAGAR, Azim A. CELEBI, Sarah J. SLANIA, Michael E. DANIELSON, Michael J. RICE, Joshua R. WURST
  • Publication number: 20120202927
    Abstract: A method of preparing a pigment includes the steps of: a) providing a mixture including: a pigment selected from the group of pigments including at least 50 wt % of C.I. Pigment Violet 23, C.I. Pigment Red 146, C.I. Pigment Red 176, C.I. Pigment Red 177, C.I. Pigment Violet 19 and C.I. Pigment Orange 13 based on the total weight of the pigment; alkyl nitrile; and at least one acid selected from the group consisting of sulfuric acid and chlorosulfuric acid, with the acid present in the mixture in amount of more than 2 wt % based on the total weight of the pigment; b) heating the mixture for more than 2 hours to a temperature of at least 70° C.; and c) filtering the mixture and washing the filtrand with a washing liquid containing water until the filtrate has a pH between 4 and 7. Pigments obtainable by the method and non aqueous pigment dispersions are also disclosed.
    Type: Application
    Filed: October 15, 2010
    Publication date: August 9, 2012
    Applicant: AGFA-GEVAERT N.V.
    Inventor: Geert Deroover
  • Publication number: 20120178747
    Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.
    Type: Application
    Filed: November 14, 2006
    Publication date: July 12, 2012
    Inventors: Dianqing (Dan) Wu, Dakai Liu, James J. Donegan
  • Patent number: 8207162
    Abstract: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: June 26, 2012
    Assignee: 3M Innovative Properties Company
    Inventors: George W. Griesgraber, Sarah J. Slania
  • Publication number: 20120122804
    Abstract: The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.
    Type: Application
    Filed: March 30, 2007
    Publication date: May 17, 2012
    Applicant: Cylene Pharmaceuticals, Inc.
    Inventors: Jeffrey P. Whitten, Michael Schwaebe, Adam Siddiqui-Jain, Terrance Moran
  • Publication number: 20120115848
    Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, U1, U2, U3, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Application
    Filed: October 6, 2011
    Publication date: May 10, 2012
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Robert A. Galemmo, JR., Dean Richard Artis, I, Xiaocong Michael Ye, Danielle L. Aubele, Anh P. Truong, Simeon Bowers, Roy K. Hom, Yong-Liang Zhu, R. Jeffrey Neitz, Jennifer Sealy, Marc Adler, Paul Beroza, John P. Anderson
  • Publication number: 20120116079
    Abstract: Reagents are provided for the introduction of phosphonate groups into fluorescent dyes. Methods are also provided for preparing dye conjugates.
    Type: Application
    Filed: August 29, 2011
    Publication date: May 10, 2012
    Inventors: Eugeny Lukhtanov, Alexei Vorobiev
  • Patent number: 8147725
    Abstract: The present invention provides a photochromic material which is an indeno-fused naphthopyran having a pi-conjugation extending group bonded to the 11-position of the indeno-fused naphthopyran, the pi-conjugation extending group having at least one pendent halo-substituted group bonded thereto. The pi-conjugation extending group extends the pi-conjugation system of said indeno-fused naphthopyran. The 13-position of the indeno-fused naphthopyran is substantially free of spiro-substituents. The invention further provides photochromic materials of specified structure, photochromic compositions, photochromic articles and optical elements that include the photochromic material.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 3, 2012
    Assignee: Transitions Optical, Inc
    Inventors: Anu Chopra, Jun Deng, Beon-Kyu Kim, David B. Knowles, Frank Molock, Victor A. Montes, Stephen D. Straight, Wenjing Xiao, Huayun Yu
  • Patent number: 8129525
    Abstract: Reactive fluorescent dyes compositions and methods of using same are disclosed. Nile Red nucleus dyes are disclosed having thiol-reactive groups. Nile Red nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: March 6, 2012
    Assignee: Becton Dickinson and Company
    Inventors: J. Bruce Pitner, Douglas B. Sherman, Arounaguiry Ambroise, Joseph Thomas
  • Publication number: 20120010404
    Abstract: The present invention provides oxazine dyes, processes for preparing the oxazine dyes, intermediates that may be utilized in the processes for preparing the oxazine dyes, and methods for using the oxazine dyes.
    Type: Application
    Filed: June 4, 2009
    Publication date: January 12, 2012
    Applicant: SIGMA-ALDRICH CO.
    Inventor: Alexei Toutchkine
  • Publication number: 20110293654
    Abstract: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    Type: Application
    Filed: August 2, 2011
    Publication date: December 1, 2011
    Inventors: George W. Griesgraber, Tushar A. Kshirsagar, Sarah J. Slania, Michael E. Danielson
  • Patent number: 8039466
    Abstract: The invention relates to novel chimeric antibiotics of formula I wherein R1 represents OH, OPO3H2 or OCOR5; R2 represents H, OH or OPO3H2; R3 represents H or halogen; R4 is H, (C1-C3)alkyl, or cycloalkyl; R5 represents piperidin-4-yl or R5 is the residue of a naturally occurring amino acid, of the enantiomer of a naturally occurring amino acid or of dimethylaminoglycine; n is 0 or 1; and to salts (in particular pharmaceutically acceptable salts) of compounds of formula I. These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).
    Type: Grant
    Filed: November 23, 2007
    Date of Patent: October 18, 2011
    Assignee: Actelion Pharmaceutical Ltd.
    Inventors: Christian Hubschwerlen, Philippe Panchaud, Jean-Luc Specklin
  • Publication number: 20110224431
    Abstract: Provided herein are triazolium carbine catalysts useful for asymmetric hydration, fluorination, and deuteration, and processes for their preparation. Also provided are synthetic reactions in which these catalysts are used, in particular, in stereoselective formation of carbon-chlorine, carbon-hydrogen, carbon-fluorine, and carbon-deuterium bonds.
    Type: Application
    Filed: February 3, 2011
    Publication date: September 15, 2011
    Applicant: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Tomislav Rovis, Harit U. Vora
  • Publication number: 20110207711
    Abstract: The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: July 27, 2009
    Publication date: August 25, 2011
    Inventors: Jason Katz, James Jewell, Joon Jung, Solomon Kattar, Yongquan Hou, Rachel MacCoss, Satoru Ito